Letters5 December 2006Hyperlactatemia due to NevirapineGeorge Panos, MD, PhD, Petros Kopterides, MD, and Matthew E. Falagas, MD, MSc, DScGeorge Panos, MD, PhDFrom 1st IKA Hospital and “Attikon” University Hospital and Alfa Institute of Biomedical Sciences, Athens, Greece, and Tufts University School of Medicine, Boston, Massachusetts.Search for more papers by this author, Petros Kopterides, MDFrom 1st IKA Hospital and “Attikon” University Hospital and Alfa Institute of Biomedical Sciences, Athens, Greece, and Tufts University School of Medicine, Boston, Massachusetts.Search for more papers by this author, and Matthew E. Falagas, MD, MSc, DScFrom 1st IKA Hospital and “Attikon” University Hospital and Alfa Institute of Biomedical Sciences, Athens, Greece, and Tufts University School of Medicine, Boston, Massachusetts.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-145-11-200612050-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Hyperlactatemia is a well-known adverse reaction in HIV-infected patients who are treated with nucleoside analogue reverse transcriptase inhibitors (NRTIs) (1). However, data on its association with the other 2 widely used classes of antiretroviral agents, nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors, are inconclusive. To our knowledge, no cases of hyperlactatemia secondary to nevirapine use have been reported to date.Objective: To describe a patient with nevirapine-induced hyperlactatemia who gradually recovered after cessation of treatment.Methods and Findings: A 36-year-old man received a diagnosis of HIV infection in November 2000 and began receiving azidothymidine–lamivudine–nevirapine in January 2001. He ...